Perspective Therapeutics Reports Positive Interim Results for [212Pb]VMT-α-NET in Neuroendocrine Tumor Trial
Reuters
Oct 20, 2025
<a href="https://laohu8.com/S/CATX">Perspective Therapeutics</a> Reports Positive Interim Results for [212Pb]VMT-α-NET in Neuroendocrine Tumor Trial
Perspective Therapeutics Inc. has announced updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors. The data were presented at the European Society for Medical Oncology (ESMO) Congress 2025. According to the company, [212Pb]VMT-α-NET continues to be well-tolerated at the 5 mCi dose. The interim results show an objective response rate of 44% (7 of 16 patients) in Cohort 2, with 14 of the 16 patients remaining free from progression and continuing on the study at a median follow-up of 41 weeks. Initial efficacy data for an additional 23 patients in Cohort 2 and 8 patients in Cohort 3 are expected during 2026. Perspective Therapeutics will hold a webcast conference call on October 20, 2025, to discuss the presented data and future clinical milestones.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-242912), on October 20, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.